Connect
← Return to Evenity and breast cancer recurrence
Discussion
Evenity and breast cancer recurrence
Osteoporosis & Bone Health | Last Active: Feb 20 8:03am | Replies (23)Comment receiving replies
@kathleen1314 Thank you. Could you please post your source for this information? Where did you find this?
Replies to "@kathleen1314 Thank you. Could you please post your source for this information? Where did you find..."
@naturegirl5
Please remember that this is in theory only no population studies or controlled studies on patients, but this is where Dr. Ott found the information which concerned her. Plus I never mentioned Dr Ott to the Ai; it mentioned it to me.
I think that this is what you need:
https://pmc.ncbi.nlm.nih.gov/articles/PMC10236625/
In academic research, the link between Evenity (romosozumab) and bone metastases is primarily investigated through its mechanism as a sclerostin inhibitor, which activates the Wnt/β-catenin signaling pathway(https://pmc.ncbi.nlm.nih.gov/articles/PMC10236625/)
Connect
@naturegirl5
Which part? The tie of Evenity to possible bone metastases?
Remember that this was in answer to what DR. Susan Ott has said as referenced by the poster. My reply was that Dr. Ott was actually concerned about bone metastastes not breast cancer. And I provided the reasoning for Dr. Ott's theory.